{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzalutamide+%28Xtandi%29", "query": { "intervention": "Enzalutamide (Xtandi)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 288, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzalutamide+%28Xtandi%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T08:11:06.636Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06844383", "title": "A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer (Adenocarcinoma)", "mCRPC (Metastatic Castration-resistant Prostate Cancer)" ], "interventions": [ { "name": "Talazoparib with enzalutamide", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prostate Cancer Clinical Trials Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 126, "start_date": "2026-05-04", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 8, "location_summary": "Duarte, California • La Jolla, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06844383" }, { "nct_id": "NCT03899467", "title": "The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castrate Resistant Prostate Cancer (mCRPC)", "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "GT0918", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Suzhou Kintor Pharmaceutical Inc,", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 61, "start_date": "2019-05-30", "completion_date": "2022-09-19", "has_results": true, "last_update_posted_date": "2024-02-12", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 10, "location_summary": "Athens, Georgia • Louisville, Kentucky • Towson, Maryland + 7 more", "locations": [ { "city": "Athens", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Towson", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899467" }, { "nct_id": "NCT03768063", "title": "A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "FAP IL2V", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Emactuzumab", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2019-02-28", "completion_date": "2028-07-05", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 7, "location_summary": "Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03768063" }, { "nct_id": "NCT04399876", "title": "Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Radical Prostatectomy" ], "interventions": [ { "name": "Microdevice", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "MALE", "summary": "22 Years and older · Male only" }, "enrollment_count": 35, "start_date": "2020-06-22", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04399876" }, { "nct_id": "NCT06136624", "title": "Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1310, "start_date": "2023-12-31", "completion_date": "2030-02-15", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 48, "location_summary": "Orange, California • Palo Alto, California • Riverside, California + 41 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136624" }, { "nct_id": "NCT04821622", "title": "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "talazoparib plus enzalutamide", "type": "DRUG" }, { "name": "Placebo plus enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 599, "start_date": "2021-05-12", "completion_date": "2027-08-28", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04821622" }, { "nct_id": "NCT03734653", "title": "Testosterone Therapy in Castration Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Prostate Cancer", "Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Transdermal Testosterone", "type": "DRUG" }, { "name": "Standard of Care, Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 30, "start_date": "2019-01-18", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03734653" }, { "nct_id": "NCT02446405", "title": "Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "NSAA", "type": "DRUG" }, { "name": "LHRHA or Surgical Castration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Sydney", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1125, "start_date": "2014-03", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446405" }, { "nct_id": "NCT02023463", "title": "Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage IIB Prostate Cancer", "Stage III Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Goserelin acetate", "type": "DRUG" }, { "name": "Leuprolide acetate", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2014-04-02", "completion_date": "2040-01-01", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02023463" }, { "nct_id": "NCT02684227", "title": "Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2016-08-24", "completion_date": "2023-09-27", "has_results": true, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-09-30T08:11:06.636Z", "location_count": 6, "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Nassau Bay", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02684227" } ] }